COVID-19 Vaccine Related Codes
COVID-19 Vaccine Codes
Preview Posting of COVID-19 Vaccine Codes and Crosswalk for Currently Authorized Vaccines and Anticipation of Potential Vaccine Availability under Emergency Use Authorization (EUA)
Note: Codes will become effective only upon EUA issuance or BLA licensure of COVID-19 vaccine(s) by the Food and Drug Administration (FDA)
The codes and crosswalk for candidate COVID-19 vaccines will be posted for preview in phases as the late-stage clinical trials for candidate vaccines progress. Additional vaccines or codes will be added to this list as they enter late-stage clinical trials or prepare applications for FDA authorization.
The following downloadable table provides a summary of the currently authorized vaccine codes and a preview of the vaccine codes that will be activated if the FDA authorizes use and ACIP votes to recommend the candidate vaccines.
To support this effort, the CDC is working closely with data partners responsible for the creation and distribution of vaccine codes and drug compendia publishers to coordinate the release of codes in advance of potential EUAs to enable systems and users that require these codes to prepare in advance.
The codes for these vaccines are also included in the vaccine code set files unless otherwise noted in the table. Additional code details and fields values are included in the vaccine code sets.
American Medical Association (AMA) COVID-19 CPT® vaccine product and administration codes are now available on the AMA web site. The CPT vaccine product codes are included in the Preview COVID-19 table and the CDC vaccine code sets. You can access further information regarding the COVID-19 CPT codes, as well as the associated coding guidance, using the following link:
Download the Preview Table for US vaccine administration only: Excel Versionexcel icon
COVID-19 vaccine codes and crosswalks are provided in anticipation of potential vaccine availability under an approved Biologics License Application (BLA), Emergency Use Authorization (EUA), or as a potential vaccine submission for EUA (Pre-EUA) as of 10/13/2021. Codes will become effective for US vaccine administrations only upon EUA issuance and/or BLA approval of COVID-19 vaccine(s) by the FDA. All CVX codes are associated to the new Vaccine Group “COVID-19.” CPT Codes shown are product codes. CPT administrative codes for doses are available on the AMA website. CPT product codes are added as the AMA approves and makes them available.
| Manufacturer | FDA Authorization (BLA, EUA, Pre-EUA) |
Sale Proprietary Name | Product Description | Unit of Sale NDC10 (UOS) | UoS Package | Unit of Use NDC10 (UOU) | UoU Presentation | CVX Code | CVX Long Description | CVX Short Description | MVX Code | CPT Product Code | CPT Description |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Products, LP | EUA-authorized (18+) | Janssen COVID-19 Vaccine | 5×10^10 viral particles/0.5 mL for adult 18+ | 59676-580-15 | CARTON, 10 MULTI-DOSE VIALS | 59676-580-05 | VIAL, MULTI-DOSE | 212 | SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL | COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL | JSN | 91303 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5×1010 viral particles/0.5 mL dosage, for intramuscular use |
| Moderna US, Inc. | EUA-authorized (18+) | Moderna COVID-19 Vaccine | 100 mcg/0.5 mL for adult 18+ (existing product) | 80777-273-99 | CARTON, 10 MULTI-DOSE VIAL 5 mL EACH | 80777-273-10 | VIAL, 5 mL, MULTI-DOSE VIAL | 207 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg or 50 mcg dose | COVID-19, mRNA, LNP-S, PF, 100 mcg or 50 mcg dose | MOD | 91301 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use |
| 80777-273-98 | CARTON, 10 MULTI-DOSE VIAL 7 mL EACH | 80777-273-15 | VIAL, 7 mL, MULTI-DOSE VIAL | ||||||||||
| Moderna US, Inc. | Pre-EUA | Moderna COVID-19 Vaccine | 50 mcg/0.25 mL for booster adult 18+ (existing product) | 80777-273-99 | CARTON, 10 MULTI-DOSE VIAL 5 mL EACH | 80777-273-10 | VIAL, 5 mL, MULTI-DOSE VIAL | 207 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg or 50 mcg dose | COVID-19, mRNA, LNP-S, PF, 100 mcg or 50 mcg dose | MOD | 91306 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use |
| 80777-273-98 | CARTON, 10 MULTI-DOSE VIAL 7 mL EACH | 80777-273-15 | VIAL, 7 mL, MULTI-DOSE VIAL | ||||||||||
| Pfizer-BioNTech | BLA-licensed (16+)
EUA-authorized (12+) |
Pfizer-BioNTech COVID-19 Vaccine | 30 mcg/0.3 mL ages 12+ (existing product) | 59267-1000-2 | CARTON, 195 MULTI-DOSE VIALS | 59267-1000-1 | MULTI-DOSE VIAL | 208 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | PFR | 91300 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use |
| 59267-1000-3 | CARTON, 25 MULTI-DOSE VIALS | ||||||||||||
| Pfizer-BioNTech | EUA-authorized (18+) | Pfizer-BioNTech COVID-19 Vaccine | 30 mcg/0.3 mL for Booster (existing product) | 59267-1000-2 | CARTON, 195 MULTI-DOSE VIALS | 59267-1000-1 | MULTI-DOSE VIAL | 208 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | PFR | 91300 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use |
| 59267-1000-3 | CARTON, 25 MULTI-DOSE VIALS | ||||||||||||
| Pfizer-BioNTech | Pre-EUA | Pfizer-BioNTech COVID-19 Vaccine | Tris-sucrose formula, 30 mcg/0.3 mL for ages 12+ | 59267-1025-2 | CARTON, 195 MULTI-DOSE VIALS | 59267-1025-1 | VIAL, 2.25 mL, MULTI-DOSE VIAL | 217 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | PFR | 91305 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
| 59267-1025-3 | CARTON, 25 MULTI-DOSE VIALS | ||||||||||||
| 59267-1025-4 | CARTON, 10 MULTI-DOSE VIALS | ||||||||||||
| Pfizer-BioNTech | Pre-EUA | Pfizer-BioNTech COVID-19 Vaccine | Tris-sucrose formula, 10 mcg/0.2 mL for ages 5 yrs to < 12 yrs | 59267-1055-2 | CARTON, 195 MULTI-DOSE VIALS | 59267-1055-1 | VIAL, 2 mL, MULTI-DOSE VIAL | 218 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose | PFR | 91307 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use |
| 59267-1055-4 | CARTON, 10 MULTI-DOSE VIALS | ||||||||||||
| Pfizer-BioNTech | Pre-EUA | Pfizer-BioNTech COVID-19 Vaccine | Tris-sucrose formula, 3 mcg/0.2 mL for ages 2 yrs to < 5 yrs | 59267-0078-2 | CARTON, 195 MULTI-DOSE VIALS | 59267-0078-1 | VIAL, 2 mL, MULTI-DOSE VIAL | 219 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2 mL dose, tris-sucrose formulation | COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose | PFR | TBD | TBD |
| 59267-0078-4 | CARTON, 10 MULTI-DOSE VIALS | ||||||||||||
| Pfizer-BioNTech | BLA-licensed (16+) | COMIRNATY | 30 mcg/0.3 mL for adult 16+ (existing formula) | 00069-1000-02 | CARTON, 195 MULTI-DOSE VIALS | 00069-1000-01 | VIAL, 2 mL, MULTI-DOSE VIAL | COMINARTY products are not orderable at this time. NDCs are listed per FDA Structured Product Label (SPL) document for the BLA licensed product. These codes are not included in CDC Vaccine Code Set files at this time. Pfizer has provided the following statement regarding the COMINARTY branded NDCs and labels:
“Pfizer received FDA BLA license on 8/23/2021 for its COVID-19 vaccine for use in individuals 16 and older (COMIRNATY). At that time, the FDA published a BLA package insert that included the approved new COVID-19 vaccine tradename COMIRNATY and listed 2 new NDCs (0069-1000-03, 0069-1000-02) and images of labels with the new tradename. |
|||||
| 00069-1000-03 | CARTON, 25 MULTI-DOSE VIALS | ||||||||||||
| AstraZeneca Pharmaceuticals LP | Pre-EUA | AstraZeneca COVID-19 Vaccine | 5×10^10 viral particles/0.5 mL, adult | No active NDC codes for U.S. Market | 210 | SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL | COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL | ASZ | 91302 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5×1010 viral particles/0.5 mL dosage, for intramuscular use | |||
| Novavax, Inc. | Pre-EUA | Novavax COVID-19 Vaccine | 5 mcg/0.5 mL, adult | No active NDC codes for U.S. Market | 211 | SARS-COV-2 (COVID-19) vaccine, Subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL per dose | COVID-19 vaccine, Subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL | NVX | 91304 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use | |||
Unspecified US COVID-19 Vaccine CVX Code
| CVX Short Description | CVX Code | CVX Long Description | Note | Vaccine Status |
|---|---|---|---|---|
| SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED | 213 | SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED | Unspecified code for COVID-19 not to be used to record patient US administration. May be used to record historic US administration if product is not known. CVX code 500 should be used to record Non-US vaccine where product is not known. | Inactive |
Download the Preview Table for Non-US vaccine administration only: Excel Versionexcel icon
Preview Posting of COVID-19 Vaccine Codes and Crosswalks to be used for Non-US vaccine administration. All COVID-19 related CVX codes are associated to the Vaccine Group “COVID-19”. Data as of 10/13/2021. CVX and MVX codes are identified for vaccines that have received emergency authorization from the World Health Organization (WHO), US Food and Drug Administration (FDA) or both. CVX codes have also been added without associated MVX for vaccines that are manufactured and administered outside the US but which have not been authorized by the WHO. The list of vaccines not authorized by the WHO may be incomplete. The list of vaccines indicated to be WHO-authorized will be updated periodically as the CDC monitors WHO published information.
| CVX Code | CVX Long Description | CVX Short Description | CVX Note | CVX Status | MVX Code | MVX Manufacturer | Product Tradename(s) |
|---|---|---|---|---|---|---|---|
| 207 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg or 50 mcg dose | COVID-19, mRNA, LNP-S, PF, 100 mcg or 50 mcg dose | EUA 12/18/2020, 2-dose vaccine. Used to record Moderna vaccines administered in the US and in non-US locations (includes tradename Spikevax) | Active | MOD | Moderna US, Inc. | Moderna COVID-19 Vaccine (non-US Spikevax) |
| 208 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | EUA 12/11/2020, 2-dose vaccine. Used to record Pfizer vaccines administered in the US and in non-US locations (includes tradename Comirnaty) | Active | PFR | Pfizer, Inc | Pfizer-BioNTech COVID-19 Vaccine (US-EUA), COMIRNATY (US-BLA), COMIRNATY (Non-US) |
| 210 | SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL | COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL | Potential EUA, 2-dose vaccine. AstraZeneca vaccine is authorized by the WHO and recognized towards immunity in the US. Non-US WHO authorized tradenames/identifiers include VAXZEVRIA, AZD1222, ChAdOx1 nCoV-19, COVISHIELD | Non-US | ASZ | AstraZeneca | AstraZeneca COVID-19 Vaccine (Non-US tradenames include VAXZEVRIA, COVISHIELD) |
| 212 | SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL | COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL | EUA 02/27/2021, 1-dose vaccine. Used to record Janssen/J&J vaccines administered in the US and in non-US locations | Active | JSN | Janssen | Janssen (J&J) COVID-19 Vaccine |
| 510 | SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (BIBP, Sinopharm) | COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) | WHO authorized pandemic vaccine. Recognized towards immunity in US | Non-US | SPH | Sinopharm-Biotech | Sinopharm (BIBP) COVID-19 Vaccine |
| 511 | SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (CoronaVac, Sinovac) | COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) | WHO authorized pandemic vaccine. Recognized towards immunity in US | Non-US | SNV | Sinovac | Coronavac (Sinovac) COVID-19 Vaccine |
| 500 | SARS-COV-2 COVID-19 Non-US Vaccine, Specific Product Unknown | COVID-19 Non-US Vaccine, Product Unknown | Pandemic Non-US Covid Administration – specific CVX or product unknown | Non-US | |||
| 501 | SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (QAZCOVID-IN) | COVID-19 IV Non-US Vaccine (QAZCOVID-IN) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 502 | SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (COVAXIN) | COVID-19 IV Non-US Vaccine (COVAXIN) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 503 | SARS-COV-2 COVID-19 Live Attenuated Virus Non-US Vaccine Product (COVIVAC) | COVID-19 LAV Non-US Vaccine (COVIVAC) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 504 | SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik Light) | COVID-19 VVnr Non-US Vaccine (Sputnik Light) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 505 | SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik V) | COVID-19 VVnr Non-US Vaccine (Sputnik V) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 506 | SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CanSino Biological Inc./Beijing Institute of Biotechnology) | COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 507 | SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences) | COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 508 | SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Jiangsu Province Centers for Disease Control and Prevention) | COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 509 | SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (EpiVacCorona) | COVID-19 PS Non-US Vaccine (EpiVacCorona) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US |
COVID-19 Emergency Use Authorization Recipient and Caregiver Fact Sheets
Preview Posting of Codes for Emergency Use Authorization (EUA) Fact Sheets for Recipients and Caregivers
Vaccine information statements (VISs), used only for licensed vaccines, will not be available for COVID-19 vaccines while they are under Emergency Use Authorization (EUA). For vaccines under an EUA, the FDA requires a vaccine-specific Fact Sheet for Recipients and Caregivers be provided to vaccine recipients or their caregivers.
The COVID-19 vaccine-related codes are provided in anticipation of potential vaccine availability under an EUA. If a vaccine is not authorized, the code will be retired.
The FDA issued Emergency Use Authorization for the Moderna COVID-19 vaccine on Friday December 18, 2020. Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:
The FDA issued Emergency Use Authorization for the Pfizer BioNTech COVID-19 vaccine on Friday December 11, 2020. Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:
The FDA issued Emergency Use Authorization for the Janssen (Johnson & Johnson) COVID-19 vaccine on Saturday February 27, 2021. Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:
The following downloadable VIS code files will include the new EUA Fact Sheet for Recipients records:
| CVX Code | EUA Recipient/Caregiver Fact Sheet Description | Document Barcode String | Edition Date | Edition Status | HTML URL | PDF URL | VIS GDTI document code |
|---|---|---|---|---|---|---|---|
| 207 | COVID-19 Moderna Vaccine EUA Recipient-Caregiver Fact Sheet | 253088698300034911210401 | 8/27/2021 | Current | https://www.cdc.gov/vaccines/covid-19/eua/modernatx.html | https://www.cdc.gov/vaccines/covid-19/eua/modernatx.pdfpdf icon | 0886983000349 |
| 208 | COVID-19 Pfizer BioNTech Vaccine EUA Recipient-Caregiver Fact Sheet | 253088698300033211210501 | 9/22/2021 | Current | https://www.cdc.gov/vaccines/covid-19/eua/pfizer.html | https://www.cdc.gov/vaccines/covid-19/eua/pfizer.pdfpdf icon | 0886983000332 |
| 212 | COVID-19 Janssen Vaccine EUA Recipient-Caregiver Fact Sheet | 253088698300036311210201 | 7/8/2021 | Current | https://www.cdc.gov/vaccines/covid-19/eua/janssen.html | https://www.cdc.gov/vaccines/covid-19/eua/janssen.pdfpdf icon | 0886983000363 |
*Edition date is the date of the barcode generated-edition date and does not reflect the exact date that the EUA Fact Sheet was issued.